Timing of Antenatal Steroid Administration and Effects on the Newborn Infant: A Retrospective Study

Abstract

Objective The timing of antenatal steroids (ANS) on short- and long-term effects on newborn infants was evaluated.

Study Design This study was conducted at the University of Cincinnati Medical Center Level-III Neonatal Intensive Care Unit by reviewing the medical records of all women with history of ANS exposure from January 2015 to December 2018. We compared outcomes of newborns delivered within the ideal therapeutic window of 24 hours to 7 days (within window [WW]) after administration to those exposed and delivered outside the therapeutic window (outside window primary group [OWP]). Outcomes included anthropometrics, blood sugars, thyroid hormone profile, and neonatal morbidities.

Results A total of 669 patients were identified as having received at least two doses of ANS. Two-thirds of them delivered within the ideal therapeutic window. Significant differences were found in anthroprometrics including lower birth weight, shorter length, and smaller head circumferences in those born within the window compared with those outside the window. Derangements in glucose homeostasis requiring treatment and elevations of thyroid stimulating hormone (TSH) were seen in infants born outside the ideal therapeutic window compared with those born within the therapeutic window. No differences were found in neonatal morbidities including severe intraventricular hemorrhage (sIVH), necrotizing enterocolitis (NEC), need for resuscitation, exogenous surfactant administration, continuous positive airway pressure (CPAP), mechanical ventilation, bronchopulmonary dysplasia (BPD), or periventricular leukomalacia (PVL). After controlling for selected covariates, only birth length was different between the groups.

Conclusion Effects on anthropometrics, glucose homeostasis, and thyroid function support the need to develop new or refine existing risk stratification systems to time the administration of antenatal steroids. Better targeting of women and fetuses may confer the benefits of systemic corticosteroids while mitigating the risks of adverse effects.

Key Points

• The timing of antenatal steroids on short and long-term effects on newborn infants was evaluated.

• Differences were found in anthroprometrics, glucoses, and thyroid function.

• No differences were found in neonatal morbidities.

Keywords

antenatal steroids - respiratory distress syndrome - intraventricular hemorrhage - newborn screening - neonatal hypoglycemia

Publication History

Received: 06 August 2020

Accepted: 28 October 2020

Article published online:
07 December 2020

• References

• 1 Alexander N, Rosenlöcher F, Stalder T. et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab 2012; 97 (10) 3538-3544
• 2 Paules C, Pueyo V, Martí E. et al. Threatened preterm labor is a risk factor for impaired cognitive development in early childhood. Am J Obstet Gynecol 2017; 216 (02) 157.e1-157.e7
• 3 Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Implementation of the use of antenatal corticosteroids in the late preterm birth period in women at risk for preterm delivery. Am J Obstet Gynecol 2016; 215 (02) B13-B15
• 4 American College of Obstetricians and Gynecologists. Antenatal corticosteroid therapy for fetal maturation. Committee Opinion No. 713. Accessed November 11, 2020 at: https://www.acog.org/-/media/project/acog/acogorg/clinical/files/committee-opinion/articles/2017/08/antenatal-corticosteroid-therapy-for-fetal-maturation.pdf
• 5 Gyamfi-Bannerman C, Thom EA, Blackwell SC. et al; NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374 (14) 1311-1320
• 6 Stutchfield P, Whitaker R, Russell I. Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331 (7518): 662
• 7 Schmidt AF, Kannan PS, Bridges JP. et al. Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques. Sci Rep 2019; 9 (01) 9039
• 8 Asztalos E. Antenatal corticosteroids: a risk factor for the development of chronic disease. J Nutr Metab 2012; 2012: 930591
• 9 Rodriguez A, Wang Y, Ali Khan A, Cartwright R, Gissler M, Järvelin MR. Antenatal corticosteroid therapy (ACT) and size at birth: A population-based analysis using the Finnish Medical Birth Register. PLoS Med 2019; 16 (02) e1002746
• 10 Murphy KE, Hannah ME, Willan AR. et al. MACS Collaborative Group. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet 2008; 372 (9656): 2143-2151
• 11 Makhija NK, Tronnes AA, Dunlap BS, Schulkin J, Lannon SM. Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol. Am J Obstet Gynecol 2016; 214 (01) 120.e1-120.e6
• 12 Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab 2009; 23 (06) 793-800
• 13 Kuo T, McQueen A, Chen TC, Wang JC. Regulation of glucose homeostasis by glucocorticoids. Adv Exp Med Biol 2015; 872: 99-126
• 14 Jobe AH. Antenatal corticosteroids – a concern for lifelong outcomes. J Pediatr 2020; 217: 184-188
• 15 Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3: CD004454
• 16 Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50 (04) 515-525
• 17 World Health Organization. WHO Recommendations on Interventions to Improve Preterm Birth Outcomes. Accessed November 11, 2020 at: https://apps.who.int/iris/bitstream/handle/10665/183037/9789241508988_eng.pdf;jsessionid=0A4EC0DB71BA548C6A990E2C9FFD0288?sequence=1
• 18 Adams TM, Kinzler WL, Chavez MR, Vintzileos AM. The timing of administration of antenatal corticosteroids in women with indicated preterm birth. Am J Obstet Gynecol 2015; 212 (05) 645.e1-645.e4
• 19 Pettit KE, Tran SH, Lee E, Caughey AB. The association of antenatal corticosteroids with neonatal hypoglycemia and hyperbilirubinemia. J Matern Fetal Neonatal Med 2014; 27 (07) 683-686
• 20 LaFranchi S. Thyroid function in the preterm infant. Thyroid 1999; 9 (01) 71-78
• 21 Kaluarachchi DC, Zhao Q, Colaizy TT. Antenatal steroids and thyroid hormone function in preterm infants. J Perinatol 2018; 38 (11) 1466-1470
• 22 Davis EP, Waffarn F, Uy C, Hobel CJ, Glynn LM, Sandman CA. Effect of prenatal glucocorticoid treatment on size at birth among infants born at term gestation. J Perinatol 2009; 29 (11) 731-737
• 23 Braun T, Sloboda DM, Tutschek B. et al. Fetal and neonatal outcomes after term and preterm delivery following betamethasone administration. Int J Gynaecol Obstet 2015; 130 (01) 64-69
• 24 Audette MC, Challis JRG, Jones RL, Sibley CP, Matthews SG. Synthetic glucocorticoid reduces human placental system a transport in women treated with antenatal therapy. J Clin Endocrinol Metab 2014; 99 (11) E2226-E2233